for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

小野薬品工業株式会社

4528.T

現在値

3,343.00JPY

変化

-155.00(-4.43%)

出来高

2,074,000

本日のレンジ

3,343.00

 - 

3,481.00

52週レンジ

2,495.00

 - 

3,990.00

∙ 約20分前の相場を表示しています。

適時開示

SK Biopharmaceuticals says Co And Ono Pharmaceutical Enter Licensing Agreement For Cenobamate In Japan

Oct 13 (Reuters) - SK Biopharmaceuticals Co Ltd <326030.KS>::SK BIOPHARMACEUTICALS, ONO PHARMACEUTICAL ENTER LICENSING AGREEMENT FOR CENOBAMATE IN JAPAN.SK BIOPHARMACEUTICALS CO LTD - CO, ONO PHARMACEUTICAL COLLABORATE TO DEVELOP AND COMMERCIALIZE CENOBAMATE.SK BIOPHARMACEUTICALS CO LTD - SK BIOPHARMACEUTICALS TO RECEIVE AN UPFRONT PAYMENT OF JPY 5 BILLION FROM ONO.SK BIOPHARMACEUTICALS - SK BIOPHARMACEUTICALS TO RECEIVE FUTURE MILESTONES OF UP TO JPY 48.1 BILLION, ROYALTIES ON NET SALES FROM ONO.SK BIOPHARMACEUTICALS - WILL CONDUCT PHASE 3 CLINICAL STUDY FOR PARTIAL-ONSET SEIZURES IN ADULTS IN NORTHEAST ASIA.

Bayer, Bristol-Myers Squibb And Ono Pharmaceutical Enter Into A Clinical Collaboration Agreement

July 18 (Reuters) - Ono Pharmaceutical Co Ltd <4528.T>::BAYER, BRISTOL-MYERS SQUIBB AND ONO PHARMACEUTICAL ENTER INTO A CLINICAL COLLABORATION AGREEMENT TO INVESTIGATE STIVARGA® (REGORAFENIB) AND OPDIVO® (NIVOLUMAB) AS COMBINATION THERAPY IN PATIENTS WITH METASTATIC COLORECTAL CANCER.BRISTOL-MYERS SQUIBB CO - COMPANIES PLAN INDICATION-SEEKING TRIAL.BRISTOL-MYERS SQUIBB CO - FURTHER TERMS OF CLINICAL COLLABORATION WERE NOT DISCLOSED..BRISTOL-MYERS - COMBINATION OF REGORAFENIB, NIVOLUMAB VERSUS. REGORAFENIB TO BE EVALUATED IN PATIENTS WITH MICRO-SATELLITE METASTATIC COLORECTAL CANCER.BRISTOL-MYERS - DATA SEEN IN REGONIVO WARRANT FURTHER EXPLORATION OF COMBINATION OF REGORAFENIB AND NIVOLUMAB IN PATIENTS WITH COLORECTAL CANCER.

Schrödinger Gets Milestone Payment From Ono

July 12 (Reuters) - Schrödinger::SCHRÖDINGER RECEIVES MILESTONE PAYMENT FROM ONO AS COLLABORATIVE PROGRAM ADVANCES.

Forty Seven & Ono Pharmaceutical Co Sign Regional License Agreement

July 11 (Reuters) - Forty Seven, Inc::FORTY SEVEN, INC. AND ONO PHARMACEUTICAL CO., LTD. SIGN REGIONAL LICENSE AGREEMENT TO DEVELOP, MANUFACTURE AND COMMERCIALIZE 5F9 IN JAPAN, SOUTH KOREA, TAIWAN AND SELECT COUNTRIES IN SOUTHEAST ASIA.FORTY SEVEN - CO TO GET UP TO $120 MILLION COMBINED UPFRONT, POTENTIAL DEVELOPMENT, COMMERCIAL MILESTONE PAYMENTS, IN ADDITION TO ROYALTIES ON NET SALES.FORTY SEVEN INC - FORTY SEVEN WILL RECEIVE A ONE-TIME UPFRONT PAYMENT OF APPROXIMATELY $15.8 MILLION FROM ONO.FORTY SEVEN-ELIGIBLE TO RECEIVE UP TO ADDITIONAL ABOUT $104 MILLION AT CURRENT EXCHANGE RATES IF SPECIFIED FUTURE DEVELOPMENT MILESTONES ACHIEVED BY ONO.FORTY SEVEN INC - ONO WILL HAVE RIGHT TO PARTICIPATE IN GLOBAL CLINICAL STUDIES OF 5F9 BY BEARING DEVELOPMENT COST IN ABOVE COUNTRIES.FORTY SEVEN INC - WILL RETAIN ALL RIGHTS TO 5F9 IN REST OF WORLD INCLUDING UNITED STATES, EUROPE AND CHINA.FORTY SEVEN INC - ONO TO RECEIVE EXCLUSIVE LICENSE FOR ALL THERAPEUTIC USES OF 5F9 IN SELECT ASIAN MARKETS.

Ono Pharmaceutical Co Ltd - To Buy Back Up To 2.92% Of Own Shares Worth 30 Billion Yen And Cancel Them On Oct. 31

Ono Pharmaceutical Co Ltd <4528.T>::ONO PHARMACEUTICAL CO LTD - TO BUY BACK UP TO 2.92% OF OWN SHARES WORTH 30 BILLION YEN AND CANCEL THEM ON OCT. 31.

Vect-Horus Enters Into Collaboration And License Agreement With Ono Pharmaceutical Co Ltd

March 26 (Reuters) - Ono Pharmaceutical Co Ltd <4528.T>::VECT-HORUS ENTERS INTO COLLABORATION AND LICENSE AGREEMENT WITH ONO PHARMACEUTICAL CO., LTD..VECT-HORUS S.A.S. - VECT-HORUS WILL RECEIVE RESEARCH FEES, SUCCESS-BASED MILESTONES ON RESEARCH AND DEVELOPMENT PROGRESS.VECT-HORUS S.A.S. - VECT-HORUS WILL RECEIVE ROYALTIES ON SALES OF PRODUCTS..VECT-HORUS - ONO TO HAVE WORLDWIDE RIGHTS TO DEVELOP AND COMMERCIALIZE ANY PHARMACEUTICAL PRODUCTS ARISING OUT OF DRUG DISCOVERY COLLABORATION.

Ono Pharmaceutical says collaboration with Fate Therapeutics for two iPSC-derived CAR-T Therapies for Cancers

Sept 18(Reuters) - Ono Pharmaceutical Co Ltd <4528.T>:Says it entered into a collaboration agreement with Fate Therapeutics Inc <<<FATE.O>>>, for the joint development and commercialization of two off-the-shelf chimeric antigen receptor(CAR)-T cell product candidates for cancer.

Ono Pharmaceutical enters into license agreement with Bristol-Myers Squibb for Prostaglandin E2 receptor antagonists

Dec 14 (Reuters) - Ono Pharmaceutical Co Ltd <4528.T>:Says it entered into license agreement with Bristol-Myers Squibb Company (BMS)for Prostaglandin E2 receptor antagonists relating to Immuno-Oncology programs .Under the terms of this agreement, BMS is granted the rights to develop and commercialize ONO-4578 and other compounds from PGE2 receptor antagonist programs worldwide, except Japan, South Korea, Taiwan, China and Association of South-East Asian Nations (ASEAN)countries.In accordance with this agreement, ONO receives an upfront payment of $40 million from BMS.ONO will also receive subsequent clinical, regulatory and sales-based milestone payments, as well as royalties based on sales of the products in the countries where ONO granted BMS the rights for development and commercialization.

Bristol-Myers Squibb Granted Exclusive License By Ono Pharmaceutical For Multiple Programs Targeting Immuno-Suppressive Factors In The Tumor Microenvironment

Dec 13 (Reuters) - Bristol-Myers Squibb Co <BMY.N>::BRISTOL-MYERS SQUIBB GRANTED EXCLUSIVE LICENSE BY ONO PHARMACEUTICAL FOR MULTIPLE PROGRAMS TARGETING IMMUNO-SUPPRESSIVE FACTORS IN THE TUMOR MICROENVIRONMENT.BRISTOL-MYERS SQUIBB CO - BRISTOL-MYERS SQUIBB WILL MAKE AN UPFRONT PAYMENT OF $40 MILLION TO ONO.BRISTOL-MYERS SQUIBB-WILL BE SOLELY RESPONSIBLE FOR DEVELOPMENT, MANUFACTURING,COMMERCIALIZATION OF ONO-4578,OTHER PGE(2) RECEPTOR ANTAGONIST PRODUCTS.

Ono Pharmaceutical completes retirement of treasury shares

Oct 31(Reuters) - Ono Pharmaceutical Co Ltd <4528.T>:Says it completed retirement of 45.9 million shares (7.8 percent of outstanding) on Oct. 31.Says the total shares outstanding 543.3 million shares after the retirement.

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up